EP0594260A1 - Nucleic acid material amplification and detection - Google Patents
Nucleic acid material amplification and detection Download PDFInfo
- Publication number
- EP0594260A1 EP0594260A1 EP93202962A EP93202962A EP0594260A1 EP 0594260 A1 EP0594260 A1 EP 0594260A1 EP 93202962 A EP93202962 A EP 93202962A EP 93202962 A EP93202962 A EP 93202962A EP 0594260 A1 EP0594260 A1 EP 0594260A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- wash
- compartment
- detection site
- label
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 67
- 239000000463 material Substances 0.000 title claims abstract description 53
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 26
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 26
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 26
- 230000003321 amplification Effects 0.000 title abstract description 5
- 238000003199 nucleic acid amplification method Methods 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000005406 washing Methods 0.000 claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 44
- 239000000523 sample Substances 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 230000011664 signaling Effects 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- 238000002372 labelling Methods 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- 238000011109 contamination Methods 0.000 claims description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 34
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 239000012491 analyte Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000005499 meniscus Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical group NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- -1 poly(ethylene terephthalate) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SZXKSDXHODZTFS-UHFFFAOYSA-N 4-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-2,6-dimethoxyphenol Chemical compound COC1=C(O)C(OC)=CC(C=2NC(=C(N=2)C=2C=CC(=CC=2)N(C)C)C=2C=CC(=CC=2)N(C)C)=C1 SZXKSDXHODZTFS-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- XZTJQQLJJCXOLP-UHFFFAOYSA-M sodium;decyl sulfate Chemical compound [Na+].CCCCCCCCCCOS([O-])(=O)=O XZTJQQLJJCXOLP-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/505—Containers for the purpose of retaining a material to be analysed, e.g. test tubes flexible containers not provided for above
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0481—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure squeezing of channels or chambers
Definitions
- This invention relates to nucleic acid material amplification and detection and is more particularly concerned with reaction cuvettes or devices, and methods, used to amplify and detect such materials.
- DNA detection is described in EP-A-0 381 501 using a method wherein polymerase chain reaction (PCR) amplification of miniscule amounts of nucleic acid material, and detection of the amplified material can all occur in a single cuvette which keeps the amplified material from escaping.
- PCR polymerase chain reaction
- Six temporarily-sealed blisters, also called compartments, are provided along with passageways connecting them to a detection site in a detection compartment.
- the blisters provide, in order, a PCR reaction compartment; a first wash compartment; an enzyme-labeling compartment containing, for example, streptavidin horseradish peroxidase (hereinafter SA-HRP); a second wash compartment; a compartment containing signalling material responsive to the enzyme; and a stop solution compartment.
- SA-HRP streptavidin horseradish peroxidase
- the Roche procedure incubates "at 37°C for 15 minutes with an avidin-horseradish peroxidase conjugate", which of course corresponds to the emptying of the enzyme blister of the cuvette described in EP-A-0 381 501 for the very same purpose. Thereafter, the Roche procedure" again washed the plate four times" "to remove unbound conjugate.” This, of course, corresponds to the second wash step provided by the second wash blister disposed between the enzyme blister and the signalling material blister in the cuvette of EP-A-0 381 501.
- non-specific signal that is, signal which occurs because of either the presence of unbound nucleic acid material which is not the target, and/or unbound SA-HRP which should not be present because the target nucleic acid material is not present.
- a method of detecting amplified nucleic acid material by hybridizing such material to a detection site comprising at least one immobilized probe, labeling the hybridized and now-immobilized nucleic acid material by bringing to the detection site a label which is or activates a signalling material to produce a signal, and thereafter adding the signalling material to the detection site to produce a detectable signal, characterized in that either the labeling step is used directly after the hybridizing step without requiring a wash step in between, or the adding step is used directly after the labeling step without requiring a wash step in between.
- a device for amplifying and detecting nucleic acid material by using at least one target strand as a template comprising:- a reaction compartment for amplifying a sample of nucleic acid material; a detection site for detecting amplified nucleic acid material; storage compartments containing a label and signalling material effective to generate, in combination, a detectable signal, and passageways for fluidly connecting the reaction compartment and storage compartments with the detection site; characterized in that the device further includes no more than one wash compartment containing a wash liquid substantially free of capture, label, and signal-forming reagents used in the storage or reaction compartments, and no more than one passageway connecting the wash compartment to the detection site so that no more than one wash step is used in a sequence of steps comprising the emptying and moving of the contents of the reaction and storage compartments to the detection site.
- the invention is useful regardless of whether PCR amplification is used or not, and regardless of the presence of all the features of that cuvette, provided that no more than one wash compartment is included with no more than one intervening wash step as a result.
- wash or “wash solution” means, a solution substantially free of capture, label and signal-forming reagents used in the other compartments, that is, in either the label compartment or the signalling material compartment.
- each slug of liquid passes over the detection site(s), improving the efficiency.
- the optional shear-thinning gel which can be added as described hereinafter enhances this capability, in that it appears to create a more viscous slug which retards backward migration of the components that are removed by the slug's front boundary.
- FIG. 1 illustrates one form of this invention, in which the wash compartment and wash step in between the reaction compartment and the label compartment has been eliminated.
- a reaction cuvette or device 10 comprises an inlet port 22 for injection of patient sample liquid, which connects via a passageway 21 to a PCR reaction compartment 26.
- a seal 46 temporarily blocks flow out of compartment 26. When seal 46 is broken, liquid feeds via a passageway 44 to a detection chamber 40 having sites 41 comprising, preferably, beads anchored in place which will complex with any targeted analyte passing them from compartment 26, and then with reagents coming from the other reagent compartments.
- Those other compartments are compartments 30, 32, 34, each feeding via passageways 48 and 50 to chamber 40. Each of those passageways is temporarily sealed at 56, and contains an appropriate reagent liquid.
- the wash compartment preferably comprises a buffer, surfactants, EDTA, NaCl, and other salts.
- Compartment 26 in addition to the patient sample added by the user, preferably includes all the conventional reagents needed for PCR amplification, optionally kept in place by temporary seal 25.
- the reagents can be pre-incorporated, or added with the patient sample as the latter is introduced.
- the reagents include primers which are bound to one member of a binding pair, the other member of which appears in compartment 30 described below.
- a useful example of the binding member attached to a primer is biotin. (If present, Seal 25 is burst by injecting sample.)
- Compartment 30 comprises, preferably, a label such as an enzyme bound to a complexing agent, such as avidin, which is a member of a binding pair, the other member of that pair being bound to a primer which becomes part of a targeted analyte during amplification in the reaction compartment 26 as described above.
- a useful reagent in compartment 30 is streptavidin horseradish peroxidase (hereinafter, SA-HRP). The other member of that binding pair is then biotin.
- Labels other than enzymes are also useful.
- fluorescent, radioactive, and chemiluminescent labels are also well-known for such uses.
- Chemiluminescent labels also preferably use a compartment 34 containing signalling reagent, discussed below for enzyme labels.
- Compartment 32 preferably comprises a wash solution as the reagent.
- Compartment 34 preferably comprises signalling material, and any dye stabilizing agent which may be useful.
- a useful reagent solution in compartment 34 is a solution of a leuco dye which is a conventional substrate for the enzyme of compartment 30. H2O2 and any shear-thinning gels are also included.
- Compartment 42 is a waste-collecting compartment, optionally containing an absorbant.
- Roller 60 exemplifies the exterior pressure means used to burst each of the compartments sequentially, to sequentially advance the contents of the respective compartment to detection chamber 40. Because all of the compartments and passageways remain sealed during the processing, no leakage out of the device occurs and carry-over contamination is prevented. Sealing of port 22 is achieved by folding corner 70 about fold line 72, so that hole 74 fits over port 22 and passageway 21 is pinched off. A closure cap is then used to keep corner 70 so folded.
- a useful processor to process device 10 is shown in EP-A-0 402 994.
- Such a processor uses a support surface on which devices 10 are placed in an array, and pressure members, for example, rollers, are mounted in position to process each of the cuvettes in parallel.
- the rollers are journalled several to one or more axles for convenience, these axles being incrementally advanced by gearing.
- the support surface is horizontal or tilted up to 15° from horizontal.
- heaters can be optionally included, either in stationary form or carried with the rollers.
- one and only one wash compartment 32 is used, to provide a wash step after incubation of the SA-HRP at the sites 41 of compartment 40, to remove any unbound SA-HRP. It is thought that no wash step or wash liquid needs to be provided between the respective sequential movements of the amplified nucleic acid material and the SA-HRP, to sites 41, for the reason that each reagent directed to the detection site is effectively washed out by the next reagent entering the station. It is surprising that the small volume in each compartment is adequate to do this.
- the wash compartment can be supplemented, if desired, with additional wash liquid.
- Figure 2 is to add a wash compartment adjacent to the first wash compartment, so that initially the first wash compartment is emptied to the detection site, and then the second wash compartment. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "A" is appended.
- cuvette 10A involves the exact same features as in the embodiment of Figure 1, except that an additional temporarily-sealed compartment 36 of wash liquid is interposed between compartments 32A and 34A. Passageway 52 connects it to compartment 40A, after seal 56A of compartment 36 is burst.
- a single wash compartment but with a greater volume of wash can be used.
- cuvette 10B comprises all the features of the previously described embodiments, except there is no wash compartment at all.
- the only compartments are the thermal cycling reaction compartment 26B, the label-containing compartment 30B (with, for example, streptavidin horseradish peroxidase, and compartment 34B containing the signalling material, for example, H2O2, optionally a shear-thinning gel described immediately hereafter, and a leuco dye which reacts with the label enzyme to produce a dye.
- seals 46B and 56B are burst sequentially by roller 60B, the contents empty via passageways 44B and 48B, respectively, into detection site 40B and then into waste compartment 42B.
- an optional ingredient for inclusion with the signalling material is an approximate 0.5% agarose solution, to stabilize color formation at the detection sites in the detection compartment.
- Agarose has the shear thinning behavior that its viscosity at about this concentration drops 270mPas (27 poise) between a shear rate of 1 to 102s ⁇ 1 (more than 60% of its drop), and only another 30mPas (3 poise) for rates above 102s ⁇ 1, when measured at 40°C.
- Other shear-thinning gels of similar viscosity behavior and low percentage concentration can also be used.
- an enlarged detection site 41B comprising immobilized beads as described in the aforesaid EP-A-0 381 051.
- the amplified target nucleic acid material with a biotin tail is shown as " ⁇ B ".
- SA-HRP is shown as "A*" as a labeled avidin.
- HUT/AAV/78 cells containing one copy of HIV per cell were treated in a standard phenol chloroform extraction process to isolate the DNA, and the amount of DNA obtained was quantified on a spectrophotometer.
- the recovered DNA (100,000 copies HIV) was amplified by polymerase chain reaction (PCR) in a cocktail containing each of the primers identified below (1 ⁇ M each), buffer [10mM magnesium chloride, 50mM tris(hydroxymethyl)aminomethane (TRIS), 50mM potassium chloride, and 0.1mg/ml gelatin], 1.5mM of each of dATP, dCTP, dGTP, and dTTP deoxynucleotide triphosphates, and 40 units of DNA polymerase obtained from Thermus aquaticus .
- PCR polymerase chain reaction
- Two sets of primers were used, one set complementary to the ENV region, and one set complementary to the GAG region of the HUT/HIV DNA, as is known to be used in multiplexing.
- One primer in each set was biotinylated to facilitate detection.
- PCR protocol was carried out using 250 ⁇ l of the above cocktail in the PCR reaction blisters of PCR analytical elements of the type described in EP-A-0 381 051 and US-A-5 299 297. More specifically, the cuvette 10C of Figure 7 was used. Parts similar to those previously described bear the same reference numeral with the letter “C” appended. Thus, compartments 26C, 30C, 32C, 36C and 34C; passageways 44C, 48C, 50C and 52C; detection site 40C, and waste compartment 42C were used as described above, except for the layout, or as noted hereinafter. For one thing, PCR amplification was done in a cuvette separate from the test cuvette 10C, with the amplified material being pooled and then injected into compartment 26C for consistency of results in all replicates, for example, 32 in Example 1.
- a thermal cycling processor of the type described in EP-A-0 402 994 was used.
- the target DNA was preheated to 90°C for 10s, then denatured at 96°C for 30s and cooled to 70°C for 60s to anneal primers and produce primer extension products. The latter two steps (heating at 96°C, then 70°C) were repeated for a total of 40 cycles.
- This PCR process was replicated 64 times, and the fluid containing the newly made PCR product was transferred from the 64 PCR blisters into a common vessel to create a pool of PCR product. Samples from this pool were diluted 1:20 in the PCR buffer described above for use in the tests described hereinafter.
- a wash solution was prepared to contain 1% sodium decyl sulfate in phosphate buffered saline solution containing 10mmolar sodium phosphate, 150mmolar sodium chloride, and 1mmolar ethylenediaminetetraacetic acid, pH 7.4.
- a conjugate of streptavidin and horseradish peroxidase obtained from Zymed Labs (San Francisco, CA) was diluted 1:8000 with casein (0.5%) in a phosphate buffer solution (pH 7.3) containing thimerosal preservative (0.01%).
- a solution of 25 g of polyvinylpyrrolidone in 100ml of water was mixed with a solution of 0.20g of 4,5-bis(4-dimethylaminophenyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)imidazole blue-forming leuco dye in 1ml N,N-dimethylformamide and stirred for 1 hour.
- a poly[styrene-co-3-(p-vinylbenzylthio)propionic acid] (mole ratio 97.6:2.4, weight ratio 95:5, 1 ⁇ m average diameter) aqueous polymer particle dispersion was prepared, and an oligonucleotide described hereinafter was covalently bound to one portion of the polymer particles, and another oligonucleotide was covalently bound to another portion of the polymer particles using the procedures described in US-A-5 149 737 and in EP-A-0 462 644.
- the oligonucleotides were linked to the polymer particles through two tetraethylene glycol spacers, a 3-amino-1,2-propanediol moiety, and a thymine base. Each oligonucleotide was appended to the polymer particles through the amino group of the 3-amino-1,2-propanediol moiety to form reagents by the procedures of US-A-4 962 029.
- the polymer/oligonucleotide particle probes were mixed with a latex adhesive of poly(methyl acrylate-co-sodium 2-acrylamido-2-methylpropanesulfonate-co-2-acetoacetoxyethyl methacrylate) (90:4:6 weight ratio) at a dry weight ratio of particles to adhesive polymer of 4/0.1 (2.5% adhesive).
- the aqueous dispersion had a solids content of 4%.
- control reagent oligonucleotide sequence is a sequence from the HIV genome and was employed as a nonsense sequence. This nonsense probe should not capture any of the HUT/HIV analyte sequences, and consequently, no dye development should occur on the control reagents.
- the other probe reagent sequence was complementary to a sequence in the ENV region of the HUT/HIV DNA.
- the above reagents were used to prepare a series of analytical elements (cuvettes), each having reagent compartments (one of which is a PCR reaction blister into which the sample analyte is first introduced) a detection compartment, and a waste reservoir.
- the analytical devices were prepared by heating a sheet of poly(ethylene terephthalate)/polyethylene laminate (SCOTCHPAKTM 241, 3M Co.) at a forming station (or mold) to form an array of depressed areas (blisters) toward one side of the sheet, and a larger depressed area near the end, and at the other side of the sheet, to which a main channel ultimately leads, a main channel from the first blister to the last, and tributary channels from each blister to the main channel so that upon lamination to a cover sheet at a later time, the resulting cuvette had narrow channels leading from the depressed areas to a main channel analogous to the devices described in US-A-5 299 297.
- Each depressed area except the one at each end of the main channel was filled with an appropriate reagent composition.
- a cover sheet was laminated to form a cover over the depressed and channel areas, and sealed to create a burst seal between each depressed area (except the last one) and the channel leading from it to the main channel.
- the cover sheet was treated overall with corona discharge.
- the probe reagent formulations described above were then immediately deposited in four alternating spots on the treated surface, each spot having 0.9 to 1.1 ⁇ l of formulation noted hereinafter, in a row.
- the disposed formulations were dried for 30s in a stream of air at room temperature while heating the opposite side of the support with an iron at about 95°C.
- the cover sheet was then laminated and sealed in three steps.
- the sandwich was pressed and sealed by heating at about 149°C only around the blisters containing the reagent solutions and around the waste blister.
- the formation of the sample-receiving PCR blister, including burst seals, and the channels was completed by heating the test pack between appropriately shaped heating jaws at about 163°C.
- the third step was the formation of perimeter seals around the test pack, and resealing all blister perimeter seals using a top plate temperature of 199°C while the bottom plate remained at ambient temperature.
- the channels and blisters formed in the completed test pack (or element) were located so that passage of a roller across the portion of the element containing the reagent blisters would sequentially burst the seals of the blisters and force the reagent from each blister into and along an exit channel to the main channel leading to the area containing the capture probes.
- the finished element was inverted so that the cover sheet containing the capture probe spots (deposits) is the bottom of the finished element with the probe deposits properly aligned in the main channel to form a detection station.
- the four probe spots were located in different positions of the main channel in several samples.
- a last waste compartment located at the end of the main channel was larger than the others and fitted with an absorbent to be a reservoir for waste fluids, for both Example 1 and the Comparative Example.
- Example 1 The completed cuvettes of Example 1 and the Comparative Example were used to evaluate the reagent formulations as follows: A blister in each test device was filled (190-210 ⁇ l) with a 20X dilution of the PCR product described above and processed as follows:
- the analyte was preheated to 95°C for 120s and its blister rolled to break the seal and advance the solution to the detection station (probe deposits).
- the analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the SA-HRP conjugate in the second blister was preheated to 65°C.
- the conjugate blister was rolled, the seal broken, and the solution directed to the detection area to displace the analyte.
- the third blister containing the first wash solution preheated to 55°C was broken and the wash directed to the detection station and held there for 5min while the second wash solution was preheated to 55°C. Then the blister containing the second wash solution was broken and the wash directed to the detection station.
- the blister containing the dye signal-forming composition was rolled without preheating, and the seal broken, and the composition directed to the detection station where the color scores were read after a 5min incubation period using a color chart as described hereinbelow.
- the color scores are recorded in Table I and presented graphically in Figure 5A.
- the blister containing the analyte in each element was preheated to about 95°C for 120s and then rolled to break the seal and advance the solution to the area containing the four immobilized deposits of probe reagents, that is, the two control probes and the two HUT/HIV probes deposited with adhesive.
- probe reagents that is, the two control probes and the two HUT/HIV probes deposited with adhesive.
- the analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the blister containing the wash solution was preheated to 55°C. Then the wash solution blister was rolled to break the seal and direct the wash solution into the detection area to clean out the main channel and to remove unbound analyte from the detection area.
- the seal of the streptavidin/horseradish peroxidase conjugate blister was rolled and broken and the solution directed to the detection area where it binds to the immobilized biotinylated analyte over a 5min period.
- the second wash composition was preheated to 55°C, and the seal of the blister was then broken with the roller and directed to the detection station where it displaced the unbound label.
- the seal of the dye signal-forming composition in the last blister was broken with the roller, and the fluid directed to the detection station where it displaced the second wash solution.
- Dye formation on the probe deposits was allowed to proceed for 5 minutes before reading color density scores. The color of each probe deposit was evaluated by comparison of the wet dye density with a color chart where 0 is no density and 10 is the highest density. The color scores are recorded in Table II and presented graphically in the graph of Figure 5B.
- Example 1 HIV REPLICATE LTR ENV LTR ENV 1 0.5 7 0.5 6.5 2 0 6.5 0 4 3 0.5 6.5 0.5 6.5 4 1 6.5 1 6.5 5 1 6.5 1 6.5 6 0.5 6.5 0.5 6 7 0.5 5 0.5 5.5 8 0.5 6.5 0.5 6 9 1 5 1 4 10 0.5 5 0.5 5 11 0.5 7 0.5 6.5 12 0.5 6 0.5 6 13 0.5 7 0.5 6.5 14 0.5 6 0.5 7 15 0.5 2 0 2 16 0.5 7 0.5 6.5 Average 6.0 5.69 TABLE II Comparative Example - HIV REPLICATE LTR ENV LTR ENV 1 0.5 5 0.5 5.5 2 0.5 2 0.5 6 3 0.5 6.5 0.5 5.5 4 1 6 1 6 5 0.5 2 0.5 2 6 1 7 1 6 7 1 7 1 5 8 1 7 1 6 9 1 3 1 7 10 1 7
- Two sets of PCR analytical cuvettes were prepared by the procedures of Example 1 with the following exceptions: 1.
- a third probe composition was prepared by the procedures of Example 1 to contain a sequence complementary to a sequence from the GAG region of the HUT/HIV DNA. 2. Only one spot (deposit) of each of the 3 probes was incorporated in each element, in the order of (1) new probe from the GAG region as described above, (2) control probe of Example 1, and (3) reagent probe of Example 1. 3.
- One set of cuvettes was 5-blister cuvettes in the reverse wash format of Example 1 (SA-HRP conjugate in the second blister and wash in the third blister), and the cuvettes in that set were processed as described in Example 1. 4.
- the second set of cuvettes used only 3 reagent compartments and no wash compartments, as shown in Figure 3. They contained the same compositions, including the analyte composition from the pool, and same amounts as the corresponding compositions in the first set of elements of Example 1 (the set with the conventional wash format), and the blisters were in the following order: Blister ( Figure 7) Content 26C PCR analyte 30C SA-HRP 32C Dye-forming detection composition
- the cuvettes in the second set were processed as follows: The analyte in the PCR blister was preheated to 95°C for 120s, and the blister was rolled to break the seal and direct the analyte to the 3 probe deposits in the detection station. Hybridization at 42°C was allowed to proceed for 5min while the SA-HRP solution in the second blister was preheated to 65°C. The second blister was then rolled to break the seal and the solution directed through the channels to the detection station. The conjugate was incubated over the detection station for 5min, then the blister containing the dye-forming detection dispersion was rolled without preheating to break the seal and direct the dispersion to the detection station to displace the SA-HRP.
- the 3-blister configuration allows for use of less reagents, a smaller unit manufacturing cost, less cuvette storage space, shorter processing times, and a smaller, less complex processor.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
- This invention relates to nucleic acid material amplification and detection and is more particularly concerned with reaction cuvettes or devices, and methods, used to amplify and detect such materials.
- DNA detection is described in EP-A-0 381 501 using a method wherein polymerase chain reaction (PCR) amplification of miniscule amounts of nucleic acid material, and detection of the amplified material can all occur in a single cuvette which keeps the amplified material from escaping. Six temporarily-sealed blisters, also called compartments, are provided along with passageways connecting them to a detection site in a detection compartment. The blisters provide, in order, a PCR reaction compartment; a first wash compartment; an enzyme-labeling compartment containing, for example, streptavidin horseradish peroxidase (hereinafter SA-HRP); a second wash compartment; a compartment containing signalling material responsive to the enzyme; and a stop solution compartment. Each of these is caused to empty into the detection compartment in the order indicated, where a detection site is used to capture the amplified nucleic acid material and to generate a detectable signal.
- The use of the two wash compartments to provide two wash steps is consistent with all conventional approaches to detecting nucleic acid material. For example, Vol. 30 of J. Clin. Microbiol. 845-853 (April, 1992) describes a process used by Roche (p. 846-847) as being one in which, following hybridization of biotinylated product to the solid wall surface, "we washed the
plate 4 times with wash Buffer I to remove any unhybridized product". These four washes correspond to the first wash step of the first wash blister of the cuvette of EP-A-0 381 501, since there also, any DNA or nucleic acid material "unhybridized" to the detection sites is washed off. Thereafter, the Roche procedure incubates "at 37°C for 15 minutes with an avidin-horseradish peroxidase conjugate", which of course corresponds to the emptying of the enzyme blister of the cuvette described in EP-A-0 381 501 for the very same purpose. Thereafter, the Roche procedure" again washed the plate four times" "to remove unbound conjugate." This, of course, corresponds to the second wash step provided by the second wash blister disposed between the enzyme blister and the signalling material blister in the cuvette of EP-A-0 381 501. - Such procedures, with all the washes, although quite workable, are time consuming and therefore expensive. Further, the washes introduce complications into the manufacture of the cuvette. However, they have been considered essential in order to eliminate "non-specific signal," that is, signal which occurs because of either the presence of unbound nucleic acid material which is not the target, and/or unbound SA-HRP which should not be present because the target nucleic acid material is not present.
- Thus, it has been a problem prior to this invention to come up with a detection sequence which eliminates at least one, and preferably both, of the wash steps and wash blisters heretofore needed, without causing so much noise in the detection as to make the signal unreliable.
- It has been determined that the format of the cuvette used in the methods described in EP-A-0 381 501 lends itself to eliminating one or both of the wash blisters, while providing substantially the same result. This was particularly surprising, given the substantial history which has dictated that washes are an essential step.
- More specifically, in accordance with one aspect of the present invention, there is provided a method of detecting amplified nucleic acid material by hybridizing such material to a detection site comprising at least one immobilized probe, labeling the hybridized and now-immobilized nucleic acid material by bringing to the detection site a label which is or activates a signalling material to produce a signal, and thereafter adding the signalling material to the detection site to produce a detectable signal,
characterized in that either the labeling step is used directly after the hybridizing step without requiring a wash step in between, or the adding step is used directly after the labeling step without requiring a wash step in between. - As will be apparent, "either-or" used in this context is the non-exclusive use.
- In accordance with another aspect of the present invention, there is provided a device for amplifying and detecting nucleic acid material by using at least one target strand as a template, the device comprising:-
a reaction compartment for amplifying a sample of nucleic acid material;
a detection site for detecting amplified nucleic acid material;
storage compartments containing a label and signalling material effective to generate, in combination, a detectable signal, and
passageways for fluidly connecting the reaction compartment and storage compartments with the detection site;
characterized in that the device further includes no more than one wash compartment containing a wash liquid substantially free of capture, label, and signal-forming reagents used in the storage or reaction compartments, and no more than one passageway connecting the wash compartment to the detection site so that no more than one wash step is used in a sequence of steps comprising the emptying and moving of the contents of the reaction and storage compartments to the detection site. - Accordingly, it is an advantageous, unexpected feature of the invention that a method and device for amplifying and detecting nucleic acid material are provided which avoid at least one of the washes heretofore considered necessary to produce the desired result.
- For a better understanding of the present invention, reference will now be made, by way of example only, to the accompanying drawings in which:-
- Figure 1 is a plan view of one embodiment of a reaction device constructed in accordance with the present invention;
- Figures 2 and 3 are plan views similar to that shown in Figure 1, but showing a second and third embodiment respectively of a device in accordance with the present invention;
- Figures 4A to 4C are fragmentary sectioned views illustrating a postulated mechanism for the present invention;
- Figures 5A to 5B and 6A to 6B are graphs showing repetitive color scores achieved during the practice of the invention (5A, 6A and 6B) or of a comparative example (5B); and
- Figure 7 is a plan view similar to that shown in Figure 2, but showing a modified cuvette used for the working examples.
- The description hereinafter sets forth the invention in the context of its preferred embodiments, in which a flexible cuvette or device is provided and used in the manner described in US-A-5 229 297. (Some of that disclosure is the same as that which appears in EP-A-0 381 501.)
- In addition, the invention is useful regardless of whether PCR amplification is used or not, and regardless of the presence of all the features of that cuvette, provided that no more than one wash compartment is included with no more than one intervening wash step as a result.
- As used herein, "wash" or "wash solution" means, a solution substantially free of capture, label and signal-forming reagents used in the other compartments, that is, in either the label compartment or the signalling material compartment.
- The ability of the flexible cuvette described in US-A-5 229 297 to provide the elimination of the wash step without seriously resulting in non-specific signal, is not completely understood. It is thought, however, that it results from the construction of the cuvette in a way which causes a linear passage of a slug of each successive liquid such that the front of the "slug" acts to wash off unbound reagents left by the previous "slug". Any interaction which occurs at such "front" is of little or no consequence to the signal developed at the immobilized sites.
- Furthermore, all of each slug of liquid passes over the detection site(s), improving the efficiency. The optional shear-thinning gel which can be added as described hereinafter enhances this capability, in that it appears to create a more viscous slug which retards backward migration of the components that are removed by the slug's front boundary.
- Figure 1 illustrates one form of this invention, in which the wash compartment and wash step in between the reaction compartment and the label compartment has been eliminated. A reaction cuvette or
device 10 comprises aninlet port 22 for injection of patient sample liquid, which connects via apassageway 21 to aPCR reaction compartment 26. Aseal 46 temporarily blocks flow out ofcompartment 26. Whenseal 46 is broken, liquid feeds via apassageway 44 to adetection chamber 40 having sites 41 comprising, preferably, beads anchored in place which will complex with any targeted analyte passing them fromcompartment 26, and then with reagents coming from the other reagent compartments. Those other compartments arecompartments passageways 48 and 50 tochamber 40. Each of those passageways is temporarily sealed at 56, and contains an appropriate reagent liquid. - The details of the chemicals useful in all the compartments, and at the sites 41, are explained in more detail in US-A-5 229 297. The wash compartment preferably comprises a buffer, surfactants, EDTA, NaCl, and other salts.
- In accordance with this invention, the number of necessary compartments has been simplified. Hence:
Compartment 26, in addition to the patient sample added by the user, preferably includes all the conventional reagents needed for PCR amplification, optionally kept in place bytemporary seal 25. (The reagents can be pre-incorporated, or added with the patient sample as the latter is introduced.) The reagents include primers which are bound to one member of a binding pair, the other member of which appears incompartment 30 described below. A useful example of the binding member attached to a primer is biotin. (If present, Seal 25 is burst by injecting sample.) -
Compartment 30 comprises, preferably, a label such as an enzyme bound to a complexing agent, such as avidin, which is a member of a binding pair, the other member of that pair being bound to a primer which becomes part of a targeted analyte during amplification in thereaction compartment 26 as described above. Hence, a useful reagent incompartment 30 is streptavidin horseradish peroxidase (hereinafter, SA-HRP). The other member of that binding pair is then biotin. - Labels other than enzymes are also useful. For example, fluorescent, radioactive, and chemiluminescent labels are also well-known for such uses. Chemiluminescent labels also preferably use a
compartment 34 containing signalling reagent, discussed below for enzyme labels. -
Compartment 32 preferably comprises a wash solution as the reagent. -
Compartment 34 preferably comprises signalling material, and any dye stabilizing agent which may be useful. Thus, for example, a useful reagent solution incompartment 34 is a solution of a leuco dye which is a conventional substrate for the enzyme ofcompartment 30. H₂O₂ and any shear-thinning gels are also included. -
Compartment 42 is a waste-collecting compartment, optionally containing an absorbant. -
Roller 60 exemplifies the exterior pressure means used to burst each of the compartments sequentially, to sequentially advance the contents of the respective compartment todetection chamber 40. Because all of the compartments and passageways remain sealed during the processing, no leakage out of the device occurs and carry-over contamination is prevented. Sealing ofport 22 is achieved by foldingcorner 70 aboutfold line 72, so thathole 74 fits overport 22 andpassageway 21 is pinched off. A closure cap is then used to keepcorner 70 so folded. - A useful processor to process
device 10 is shown in EP-A-0 402 994. Such a processor uses a support surface on whichdevices 10 are placed in an array, and pressure members, for example, rollers, are mounted in position to process each of the cuvettes in parallel. The rollers are journalled several to one or more axles for convenience, these axles being incrementally advanced by gearing. Preferably, the support surface is horizontal or tilted up to 15° from horizontal. Additionally, heaters can be optionally included, either in stationary form or carried with the rollers. - Thus, one and only one
wash compartment 32 is used, to provide a wash step after incubation of the SA-HRP at the sites 41 ofcompartment 40, to remove any unbound SA-HRP. It is thought that no wash step or wash liquid needs to be provided between the respective sequential movements of the amplified nucleic acid material and the SA-HRP, to sites 41, for the reason that each reagent directed to the detection site is effectively washed out by the next reagent entering the station. It is surprising that the small volume in each compartment is adequate to do this. - Alternatively (not shown), the exact same structure of Figure 1 is useful but with the wash liquid being located only in
compartment 30, so that the SA-HRP is now located incompartment 32. In this configuration, the method proceeds to directly interact the signalling material ofcompartment 34 with sites 41 immediately after incubation of the SA-HRP at those sites, with no intervening wash. The reasons why this can be done are those set forth for the previous embodiment. - In either of the embodiments, the wash compartment can be supplemented, if desired, with additional wash liquid. A convenient method of doing this, Figure 2, is to add a wash compartment adjacent to the first wash compartment, so that initially the first wash compartment is emptied to the detection site, and then the second wash compartment. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "A" is appended.
- Thus, cuvette 10A involves the exact same features as in the embodiment of Figure 1, except that an additional temporarily-sealed
compartment 36 of wash liquid is interposed betweencompartments Passageway 52 connects it tocompartment 40A, afterseal 56A ofcompartment 36 is burst. - Alternatively, a single wash compartment but with a greater volume of wash, can be used.
- It is not necessary that there be any wash compartment or any wash step resulting, as shown in Figure 3. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "B" is appended.
- Thus, Figure 3, cuvette 10B comprises all the features of the previously described embodiments, except there is no wash compartment at all. The only compartments are the thermal
cycling reaction compartment 26B, the label-containingcompartment 30B (with, for example, streptavidin horseradish peroxidase, andcompartment 34B containing the signalling material, for example, H₂O₂, optionally a shear-thinning gel described immediately hereafter, and a leuco dye which reacts with the label enzyme to produce a dye. When seals 46B and 56B are burst sequentially byroller 60B, the contents empty viapassageways detection site 40B and then intowaste compartment 42B. - In all of the embodiments, an optional ingredient for inclusion with the signalling material is an approximate 0.5% agarose solution, to stabilize color formation at the detection sites in the detection compartment. Agarose has the shear thinning behavior that its viscosity at about this concentration drops 270mPas (27 poise) between a shear rate of 1 to 10²s⁻¹ (more than 60% of its drop), and only another 30mPas (3 poise) for rates above 10²s⁻¹, when measured at 40°C. Other shear-thinning gels of similar viscosity behavior and low percentage concentration can also be used.
- As noted above, it is not completely understood how the cuvette surprisingly allows the wash steps to be eliminated, when heretofore they were considered essential between the addition of either the amplified material or the label, and the next reagent, to the detection site. Figures 4A to 4C are included to help illustrate a postulated mechanism, using, for example, the embodiment of Figure 3. However, the same principal is believed to be operative in all embodiments.
- What is shown is an
enlarged detection site 41B, comprising immobilized beads as described in the aforesaid EP-A-0 381 051. At the stage shown in Figure 4A, the amplified target nucleic acid material with a biotin tail is shown as "∼∼∼B". Such material has already been hybridized to the beads. Additionally, the compartment containing the label SA-HRP has been emptied to that site. (SA-HRP is shown as "A*" as a labeled avidin.) Some of that SA-HRP has already bound to the biotin of the target, but some is shown as unbound or "loose" on the beads and on the surface ofcompartment 40B. - When the next compartment, containing signalling material such as leuco dye (shown as "L.D.") is burst, the leuco dye advances as a "slug" 100, Figure 4B. Its leading
meniscus 102 approachessite 41B because of its motion, as shown byarrow 104. When "slug" 100 passes oversite 41B, Figure 4C, it sweeps off the unbound previous reagent (the A*) atmeniscus 102, leaving only the bound label to react at the trailing part ofslug 100 to produce dye atsite 41B. Because it isregion 110 which is read or detected, any extraneous dye produced downstream (at meniscus 102) is irrelevant. Backwards migration of such extraneous dye to the detection site is further retarded by the use of the optional shear-thinning gel described above. - The following non-exhaustive examples will help illustrate the invention.
- All examples and comparative examples had reagents prepared as follows, unless otherwise noted:
- HUT/AAV/78 cells containing one copy of HIV per cell were treated in a standard phenol chloroform extraction process to isolate the DNA, and the amount of DNA obtained was quantified on a spectrophotometer. The recovered DNA (100,000 copies HIV) was amplified by polymerase chain reaction (PCR) in a cocktail containing each of the primers identified below (1µM each), buffer [10mM magnesium chloride, 50mM tris(hydroxymethyl)aminomethane (TRIS), 50mM potassium chloride, and 0.1mg/ml gelatin], 1.5mM of each of dATP, dCTP, dGTP, and dTTP deoxynucleotide triphosphates, and 40 units of DNA polymerase obtained from Thermus aquaticus.
- Two sets of primers were used, one set complementary to the ENV region, and one set complementary to the GAG region of the HUT/HIV DNA, as is known to be used in multiplexing. One primer in each set was biotinylated to facilitate detection.
- Two tetraethylene glycol spacer groups were attached to the oligonucleotide according to the teaching of US-A-4 914 210.
- The PCR protocol was carried out using 250µl of the above cocktail in the PCR reaction blisters of PCR analytical elements of the type described in EP-A-0 381 051 and US-A-5 299 297. More specifically, the cuvette 10C of Figure 7 was used. Parts similar to those previously described bear the same reference numeral with the letter "C" appended. Thus, compartments 26C, 30C, 32C, 36C and 34C;
passageways detection site 40C, andwaste compartment 42C were used as described above, except for the layout, or as noted hereinafter. For one thing, PCR amplification was done in a cuvette separate from the test cuvette 10C, with the amplified material being pooled and then injected intocompartment 26C for consistency of results in all replicates, for example, 32 in Example 1. - A thermal cycling processor of the type described in EP-A-0 402 994 was used.
- The target DNA was preheated to 90°C for 10s, then denatured at 96°C for 30s and cooled to 70°C for 60s to anneal primers and produce primer extension products. The latter two steps (heating at 96°C, then 70°C) were repeated for a total of 40 cycles. This PCR process was replicated 64 times, and the fluid containing the newly made PCR product was transferred from the 64 PCR blisters into a common vessel to create a pool of PCR product. Samples from this pool were diluted 1:20 in the PCR buffer described above for use in the tests described hereinafter.
- A wash solution was prepared to contain 1% sodium decyl sulfate in phosphate buffered saline solution containing 10mmolar sodium phosphate, 150mmolar sodium chloride, and 1mmolar ethylenediaminetetraacetic acid, pH 7.4.
- A conjugate of streptavidin and horseradish peroxidase obtained from Zymed Labs (San Francisco, CA) was diluted 1:8000 with casein (0.5%) in a phosphate buffer solution (pH 7.3) containing thimerosal preservative (0.01%).
- A solution of 25 g of polyvinylpyrrolidone in 100ml of water was mixed with a solution of 0.20g of 4,5-bis(4-dimethylaminophenyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)imidazole blue-forming leuco dye in 1ml N,N-dimethylformamide and stirred for 1 hour. This was then added to a solution prepared by mixing 2.76g of monosodium phosphate, monohydrate dissolved in 1900ml of water, 0.2ml of diethylenetriaminepentaacetic acid solution (0.1M), and 1.51g of 4'-hydroxyacetanilide and adjusting to pH 6.82 with 50% sodium hydroxide solution. Then 2ml of 30% hydrogen peroxide was added and the mixture stirred to form a dye dispersion. Finally, 24.75ml of the resulting dye dispersion was mixed with 0.25ml of aqueous 25µM dimedone and 0.125g of agarose to produce a dye-forming composition containing 0.5% agarose. The total composition was heated and stirred at 80°C until the agarose dissolved, and then cooled to room temperature.
- A poly[styrene-co-3-(p-vinylbenzylthio)propionic acid] (mole ratio 97.6:2.4, weight ratio 95:5, 1µm average diameter) aqueous polymer particle dispersion was prepared, and an oligonucleotide described hereinafter was covalently bound to one portion of the polymer particles, and another oligonucleotide was covalently bound to another portion of the polymer particles using the procedures described in US-A-5 149 737 and in EP-A-0 462 644. The oligonucleotides were linked to the polymer particles through two tetraethylene glycol spacers, a 3-amino-1,2-propanediol moiety, and a thymine base. Each oligonucleotide was appended to the polymer particles through the amino group of the 3-amino-1,2-propanediol moiety to form reagents by the procedures of US-A-4 962 029.
- The polymer/oligonucleotide particle probes were mixed with a latex adhesive of poly(methyl acrylate-co-sodium 2-acrylamido-2-methylpropanesulfonate-co-2-acetoacetoxyethyl methacrylate) (90:4:6 weight ratio) at a dry weight ratio of particles to adhesive polymer of 4/0.1 (2.5% adhesive). The aqueous dispersion had a solids content of 4%.
- These reagent formulations were used to prepare a series of analytical devices containing the reagents as capture probes in assays for HUT/HIV. The control reagent oligonucleotide sequence is a sequence from the HIV genome and was employed as a nonsense sequence. This nonsense probe should not capture any of the HUT/HIV analyte sequences, and consequently, no dye development should occur on the control reagents. The other probe reagent sequence was complementary to a sequence in the ENV region of the HUT/HIV DNA.
- The above reagents were used to prepare a series of analytical elements (cuvettes), each having reagent compartments (one of which is a PCR reaction blister into which the sample analyte is first introduced) a detection compartment, and a waste reservoir. The analytical devices (or elements) were prepared by heating a sheet of poly(ethylene terephthalate)/polyethylene laminate (SCOTCHPAK™ 241, 3M Co.) at a forming station (or mold) to form an array of depressed areas (blisters) toward one side of the sheet, and a larger depressed area near the end, and at the other side of the sheet, to which a main channel ultimately leads, a main channel from the first blister to the last, and tributary channels from each blister to the main channel so that upon lamination to a cover sheet at a later time, the resulting cuvette had narrow channels leading from the depressed areas to a main channel analogous to the devices described in US-A-5 299 297. Each depressed area except the one at each end of the main channel was filled with an appropriate reagent composition. A cover sheet was laminated to form a cover over the depressed and channel areas, and sealed to create a burst seal between each depressed area (except the last one) and the channel leading from it to the main channel. First, however, the cover sheet was treated overall with corona discharge. The probe reagent formulations described above (Invention & Control) were then immediately deposited in four alternating spots on the treated surface, each spot having 0.9 to 1.1µl of formulation noted hereinafter, in a row. The disposed formulations were dried for 30s in a stream of air at room temperature while heating the opposite side of the support with an iron at about 95°C.
- To demonstrate the embodiment of Figure 2, 16 replicates were prepared. The blisters of each one of the sheets in the 16 replicates prepared above were filled with reagents in the example tests as follows:
Blister (Figure 7) Reagent 26C Reserved for injection of analyte (190-210µl) 30C SA-HRP conjugate (∼350µl) 32C Wash solution (∼235µl) 36C Wash solution (∼350µl) 34C Leuco dye (∼235µl) (Thus, extra wash material was supplied, but effective only to separate blister 5 fromblister 2, and not effective toseparate blister 2 fromblister 1.) - As a comparative example akin to those shown in EP-A-0 381 501 (the "stop solution" compartment having been omitted, a step clearly unnecessary for prompt readings), another set of 16 replicate cuvettes were prepared identical to Example 1, except that the positions of the first wash and the SA-HRP conjugate in
blisters - The cover sheet was then laminated and sealed in three steps. First, the sandwich was pressed and sealed by heating at about 149°C only around the blisters containing the reagent solutions and around the waste blister. The formation of the sample-receiving PCR blister, including burst seals, and the channels was completed by heating the test pack between appropriately shaped heating jaws at about 163°C. The third step was the formation of perimeter seals around the test pack, and resealing all blister perimeter seals using a top plate temperature of 199°C while the bottom plate remained at ambient temperature. The channels and blisters formed in the completed test pack (or element) were located so that passage of a roller across the portion of the element containing the reagent blisters would sequentially burst the seals of the blisters and force the reagent from each blister into and along an exit channel to the main channel leading to the area containing the capture probes. The finished element was inverted so that the cover sheet containing the capture probe spots (deposits) is the bottom of the finished element with the probe deposits properly aligned in the main channel to form a detection station. The four probe spots were located in different positions of the main channel in several samples.
- A last waste compartment located at the end of the main channel was larger than the others and fitted with an absorbent to be a reservoir for waste fluids, for both Example 1 and the Comparative Example.
- The completed cuvettes of Example 1 and the Comparative Example were used to evaluate the reagent formulations as follows:
A blister in each test device was filled (190-210µl) with a 20X dilution of the PCR product described above and processed as follows: - The analyte was preheated to 95°C for 120s and its blister rolled to break the seal and advance the solution to the detection station (probe deposits). The analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the SA-HRP conjugate in the second blister was preheated to 65°C. The conjugate blister was rolled, the seal broken, and the solution directed to the detection area to displace the analyte. After 5min, the third blister containing the first wash solution preheated to 55°C was broken and the wash directed to the detection station and held there for 5min while the second wash solution was preheated to 55°C. Then the blister containing the second wash solution was broken and the wash directed to the detection station. Finally, the blister containing the dye signal-forming composition was rolled without preheating, and the seal broken, and the composition directed to the detection station where the color scores were read after a 5min incubation period using a color chart as described hereinbelow. The color scores are recorded in Table I and presented graphically in Figure 5A.
- The blister containing the analyte in each element was preheated to about 95°C for 120s and then rolled to break the seal and advance the solution to the area containing the four immobilized deposits of probe reagents, that is, the two control probes and the two HUT/HIV probes deposited with adhesive. The analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the blister containing the wash solution was preheated to 55°C. Then the wash solution blister was rolled to break the seal and direct the wash solution into the detection area to clean out the main channel and to remove unbound analyte from the detection area. Then, without preheating, the seal of the streptavidin/horseradish peroxidase conjugate blister was rolled and broken and the solution directed to the detection area where it binds to the immobilized biotinylated analyte over a 5min period. During this time, the second wash composition was preheated to 55°C, and the seal of the blister was then broken with the roller and directed to the detection station where it displaced the unbound label. Finally, the seal of the dye signal-forming composition in the last blister was broken with the roller, and the fluid directed to the detection station where it displaced the second wash solution. Dye formation on the probe deposits was allowed to proceed for 5 minutes before reading color density scores. The color of each probe deposit was evaluated by comparison of the wet dye density with a color chart where 0 is no density and 10 is the highest density. The color scores are recorded in Table II and presented graphically in the graph of Figure 5B.
- (The letters "LTR" and "ENV" of Tables I and II represent, respectively, the control nonsense probe deposits and the probe deposits complementary to the ENV region of the HIV genome in the analyte. These represent each of the 4 bead sites in the detection compartment. Left to right, the first bead encountered by flowing liquid was "LTR". The second was "ENV"; third, "LTR", and finally the last, "ENV" in the right hand column.)
TABLE I Example 1 - HIV REPLICATE LTR ENV LTR ENV 1 0.5 7 0.5 6.5 2 0 6.5 0 4 3 0.5 6.5 0.5 6.5 4 1 6.5 1 6.5 5 1 6.5 1 6.5 6 0.5 6.5 0.5 6 7 0.5 5 0.5 5.5 8 0.5 6.5 0.5 6 9 1 5 1 4 10 0.5 5 0.5 5 11 0.5 7 0.5 6.5 12 0.5 6 0.5 6 13 0.5 7 0.5 6.5 14 0.5 6 0.5 7 15 0.5 2 0 2 16 0.5 7 0.5 6.5 Average 6.0 5.69 TABLE II Comparative Example - HIV REPLICATE LTR ENV LTR ENV 1 0.5 5 0.5 5.5 2 0.5 2 0.5 6 3 0.5 6.5 0.5 5.5 4 1 6 1 6 5 0.5 2 0.5 2 6 1 7 1 6 7 1 7 1 5 8 1 7 1 6 9 1 3 1 7 10 1 7 1 6 11 0.5 1 0.5 4 12 1 7 0.5 6 13 1 7 1 6.5 14 0.5 6 1 4 15 1 6.5 1 6 16 1 7 1 5.5 Average 5.44 5.44 - As is readily apparent, particularly from a comparison of Figures 5A and 5B, the elimination of the wash step after hybridizing the amplified nucleic acid material to the detection site and before adding the label reagent, did not harm the results. Indeed, better results occurred. Quantitatively, this can also be seen by averaging the second and fourth beads "ENV" in Example 1 for all 16 replicates, and comparing those with the Comparative Example. For Example 1, the average was 6.0 and 5.69, whereas for the Comparative Example it was 5.44 in both cases.
- The above results are not limited to a particular assay - they also occur when assaying for, for example, CMV (cytomegalovirus). It is for this reason that the oligonucleotide sequences have not been specifically identified as it is believed to be immaterial which assay is used to show that one or both washes can be eliminated.
- It has been shown that results comparable to those of Example 1 occur if the second wash compartment is omitted, to produce a cuvette as shown in Figure 1. That is, in such a cuvette a wash compartment and step occurs only between the label compartment and step (using SA-HRP) and the signalling material compartment and step (using a leuco dye and H₂O₂).
- Similarly, it has been shown that such a 4-compartment cuvette with only one wash compartment, but located between the reaction compartment used to amplify the nucleic acid material, and the label compartment, produces results which are comparable to the conventional construction having a wash compartment (and step) after each of the reaction compartment (hybridizing step) AND the label compartment (labeling step).
- Two sets of PCR analytical cuvettes were prepared by the procedures of Example 1 with the following exceptions:
1. A third probe composition was prepared by the procedures of Example 1 to contain a sequence complementary to a sequence from the GAG region of the HUT/HIV DNA.
2. Only one spot (deposit) of each of the 3 probes was incorporated in each element, in the order of (1) new probe from the GAG region as described above, (2) control probe of Example 1, and (3) reagent probe of Example 1.
3. One set of cuvettes was 5-blister cuvettes in the reverse wash format of Example 1 (SA-HRP conjugate in the second blister and wash in the third blister), and the cuvettes in that set were processed as described in Example 1.
4. The second set of cuvettes used only 3 reagent compartments and no wash compartments, as shown in Figure 3. They contained the same compositions, including the analyte composition from the pool, and same amounts as the corresponding compositions in the first set of elements of Example 1 (the set with the conventional wash format), and the blisters were in the following order:Blister (Figure 7) Content 26C PCR analyte 30C SA- HRP 32C Dye-forming detection composition - The remaining blisters or compartments were left empty.
- The cuvettes in the second set were processed as follows:
The analyte in the PCR blister was preheated to 95°C for 120s, and the blister was rolled to break the seal and direct the analyte to the 3 probe deposits in the detection station. Hybridization at 42°C was allowed to proceed for 5min while the SA-HRP solution in the second blister was preheated to 65°C. The second blister was then rolled to break the seal and the solution directed through the channels to the detection station. The conjugate was incubated over the detection station for 5min, then the blister containing the dye-forming detection dispersion was rolled without preheating to break the seal and direct the dispersion to the detection station to displace the SA-HRP. After 5min incubation of the dye dispersion in the detection station, the color scores were read using a color chart as in Example 1. The color scores for both sets of elements are recorded in Tables IIA and IIB and are presented graphically in the Graphs of Figures 6A and 6B, respectively. - The data show that the 3-blister cuvette configuration gives positive signals comparable to those of the 5-blister, wash cuvette format of Example 1; however, with slightly elevated signals on the nonsense (control) beads. This can be reduced or eliminated in the 3-blister configuration by using a larger volume of the dye-forming detection dispersion. The 3-blister configuration allows for use of less reagents, a smaller unit manufacturing cost, less cuvette storage space, shorter processing times, and a smaller, less complex processor.
TABLE IIA 5-Blister as with Example 1 REPLICATE GAG ENV LTR 1 7 7 0.5 2 7 7 1 3 7.5 7 1 4 7.5 7 0.5 5 7 7 1 TABLE IIB 3-Blister Data REPLICATE GAG ENV LTR 1 7 7 2 2 7.5 7 2 3 7 7 2.5 4 7.5 7 2.5 - The invention disclosed herein may be practised in the absence of any element which is not specifically disclosed herein.
Claims (10)
- A method of detecting amplified nucleic acid material by hybridizing such material to a detection site comprising at least one immobilized probe, labeling the hybridized and now-immobilized nucleic acid material by bringing to the detection site a label which is or activates a signalling material to produce a signal, and thereafter adding the signalling material to the detection site to produce a detectable signal,
characterized in that either the labeling step is used directly after the hybridizing step without requiring a wash step in between, or the adding step is used directly after the labeling step without requiring a wash step in between. - A method according to claim 1, and further including a step of washing the detection site with wash liquid only between the step of hybridizing the nucleic acid material and the step of labeling with the label.
- A method according to claim 1, and further including a step of washing the detection site with wash liquid only between the steps of labeling with the label and adding the signalling material.
- A method according to claim 1, wherein both the labeling step is used directly after the hybridizing step without a separate wash step in between, and the adding step is used directly after the labeling step without a separate wash step in between.
- A method according to any one of claims 1 to 4, wherein the label is an enzyme.
- A method according to claim 1, further including the step of transferring the amplified material to the detection site prior to the step of hybridizing.
- A device (10; 10A; 10B; 10C) for amplifying and detecting nucleic acid material by using at least one target strand as a template, the device (10; 10A; 10B; 10C) comprising:-
a reaction compartment (26; 26A; 26B; 26C) for amplifying a sample of nucleic acid material;
a detection site (40, 41; 40A, 41A; 40B; 40C) for detecting amplified nucleic acid material;
storage compartments (30, 32, 34; 30A, 32A, 34A, 36; 30B, 34B; 30C, 32C, 34C, 36C) containing a label and signalling material effective to generate, in combination, a detectable signal, and
passageways (44, 48, 50; 44A, 48A, 50A, 52; 44B, 48B; 44C, 48C, 50C, 52C) for fluidly connecting the reaction compartment (26; 26A; 26B; 26C) and storage compartments (30, 32, 34; 30A, 32A, 34A, 36; 30B, 34B; 30C, 32C, 34C, 36C) with the detection site (40, 41; 40A, 41A; 40B; 40C);
characterized in that the device (10; 10A; 10B; 10C) further includes no more than one wash compartment (32; 36) containing a wash liquid substantially free of capture, label, and signal-forming reagents used in the storage or reaction compartments (26, 30, 32, 34; 26A, 30A, 32A, 34A, 36; 26B, 30B, 34B; 26C, 30C, 32C, 34C, 36C), and no more than one passageway (48; 52) connecting the wash compartment (32; 36) to the detection site (40, 41; 40A, 41A; 40B; 40C) so that no more than one wash step is used in a sequence of steps comprising the emptying and moving of the contents of the reaction and storage compartments (26, 30, 32, 34; 26A, 30A, 32A, 34A, 36; 26B, 30B, 34B; 26C, 30C, 32C, 34C, 36C) to the detection site (40, 41; 40A, 41A; 40B; 40C). - A device according to claim 7, wherein the device (10B; 10C) is free of any wash compartment containing a wash liquid substantially free of capture, label, and signal-forming reagents used in storage or reaction compartments.
- A device according to claim 7, wherein all of the compartments (26, 30, 32, 34; 26A, 30A, 32A, 34A, 36; 26B, 30B, 34B; 26C, 30C, 32C, 34C, 36C), detection site (40, 41; 40A, 41A; 40B; 40C), and passageways (44, 48, 50; 44A, 48A, 50A, 52; 44B, 48B; 44C, 48C, 50C, 52C) are sealed against leakage to the exterior of the device (10; 10A; 10B; 10C) to prevent carry-over contamination.
- A device according to any one of claims 7 to 9, wherein the label is an enzyme.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96568392A | 1992-10-23 | 1992-10-23 | |
US965683 | 1992-10-23 | ||
US979569 | 1992-11-20 | ||
US07/979,569 US5422271A (en) | 1992-11-20 | 1992-11-20 | Nucleic acid material amplification and detection without washing |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0594260A1 true EP0594260A1 (en) | 1994-04-27 |
EP0594260B1 EP0594260B1 (en) | 1998-03-18 |
Family
ID=27130480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19930202962 Expired - Lifetime EP0594260B1 (en) | 1992-10-23 | 1993-10-21 | Nucleic acid material amplification and detection |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0594260B1 (en) |
JP (1) | JP3795540B2 (en) |
DE (1) | DE69317502T2 (en) |
DK (1) | DK0594260T3 (en) |
FI (1) | FI934669A (en) |
TW (1) | TW313588B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1123980A2 (en) | 2000-02-11 | 2001-08-16 | Roche Diagnostics GmbH | System for simple nucleic acid analysis |
WO2007016693A2 (en) * | 2005-08-02 | 2007-02-08 | 3M Innovative Properties Company | Flexible apparatus and method for detecting an analyte |
EP2138233A1 (en) * | 2008-06-02 | 2009-12-30 | Boehringer Ingelheim microParts GmbH | Microfluid film structure for metering liquids |
US7767447B2 (en) | 2007-06-21 | 2010-08-03 | Gen-Probe Incorporated | Instruments and methods for exposing a receptacle to multiple thermal zones |
WO2010126419A1 (en) * | 2009-04-27 | 2010-11-04 | Telefonaktiebolaget L M Ericsson (Publ) | Methods and arrangements in a wireless communication system |
US8012427B2 (en) | 2005-08-02 | 2011-09-06 | 3M Innovative Properties Company | Apparatus and method for detecting an analyte |
US8780688B2 (en) | 2009-04-27 | 2014-07-15 | Telefonaktiebolaget Lm Ericsson (Publ) | Methods and apparatus in a wireless communication system |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE363339T1 (en) * | 1998-05-01 | 2007-06-15 | Gen Probe Inc | STIRRING DEVICE FOR THE FLUID CONTENTS OF A CONTAINER |
US8615368B2 (en) | 2005-03-10 | 2013-12-24 | Gen-Probe Incorporated | Method for determining the amount of an analyte in a sample |
US9125093B2 (en) | 2005-12-22 | 2015-09-01 | Qualcomm Incorporated | Methods and apparatus related to custom control channel reporting formats |
JPWO2010106997A1 (en) | 2009-03-19 | 2012-09-20 | 株式会社カネカ | Nucleic acid detection method, kit and device |
CN103543282A (en) | 2010-07-23 | 2014-01-29 | 贝克曼考尔特公司 | System for processing samples |
US9046507B2 (en) | 2010-07-29 | 2015-06-02 | Gen-Probe Incorporated | Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure |
EP2678664B1 (en) | 2011-02-24 | 2019-08-07 | Gen-Probe Incorporated | Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector |
ES2729283T3 (en) | 2011-11-07 | 2019-10-31 | Beckman Coulter Inc | Centrifugal and workflow system |
ES2844324T3 (en) | 2011-11-07 | 2021-07-21 | Beckman Coulter Inc | Robotic arm |
BR112014010955A2 (en) | 2011-11-07 | 2017-06-06 | Beckman Coulter Inc | system and method for processing samples |
BR112014011035A2 (en) | 2011-11-07 | 2017-06-13 | Beckman Coulter, Inc. | aliquot system and workflow |
US8973736B2 (en) | 2011-11-07 | 2015-03-10 | Beckman Coulter, Inc. | Magnetic damping for specimen transport system |
KR20140091033A (en) | 2011-11-07 | 2014-07-18 | 베크만 컬터, 인코포레이티드 | Specimen container detection |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318255A2 (en) * | 1987-11-23 | 1989-05-31 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Cuvette |
EP0381501A2 (en) * | 1989-02-03 | 1990-08-08 | Eastman Kodak Company | Containment cuvette for PCR and method of use |
WO1992011390A1 (en) * | 1990-12-17 | 1992-07-09 | Idexx Laboratories, Inc. | Nucleic acid sequence detection by triple helix formation |
WO1992016659A1 (en) * | 1991-03-21 | 1992-10-01 | Eastman Kodak Company | Element and method for nucleic acid amplification and detection using adhered probes |
EP0572057A1 (en) * | 1992-05-11 | 1993-12-01 | Johnson & Johnson Clinical Diagnostics, Inc. | PCR reagent composition, test kit and methods for amplification and detection with reduced nonspecific amplification of nucleic acids |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0408738B1 (en) * | 1989-02-03 | 1994-01-19 | Eastman Kodak Company | Nucleic acid test article and its use to detect a predetermined nucleic acid |
-
1993
- 1993-08-31 TW TW82107088A patent/TW313588B/zh not_active IP Right Cessation
- 1993-10-21 DE DE1993617502 patent/DE69317502T2/en not_active Expired - Lifetime
- 1993-10-21 DK DK93202962T patent/DK0594260T3/en active
- 1993-10-21 EP EP19930202962 patent/EP0594260B1/en not_active Expired - Lifetime
- 1993-10-22 JP JP26481393A patent/JP3795540B2/en not_active Expired - Lifetime
- 1993-10-22 FI FI934669A patent/FI934669A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318255A2 (en) * | 1987-11-23 | 1989-05-31 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Cuvette |
EP0381501A2 (en) * | 1989-02-03 | 1990-08-08 | Eastman Kodak Company | Containment cuvette for PCR and method of use |
WO1992011390A1 (en) * | 1990-12-17 | 1992-07-09 | Idexx Laboratories, Inc. | Nucleic acid sequence detection by triple helix formation |
WO1992016659A1 (en) * | 1991-03-21 | 1992-10-01 | Eastman Kodak Company | Element and method for nucleic acid amplification and detection using adhered probes |
EP0572057A1 (en) * | 1992-05-11 | 1993-12-01 | Johnson & Johnson Clinical Diagnostics, Inc. | PCR reagent composition, test kit and methods for amplification and detection with reduced nonspecific amplification of nucleic acids |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1123980A2 (en) | 2000-02-11 | 2001-08-16 | Roche Diagnostics GmbH | System for simple nucleic acid analysis |
US8012427B2 (en) | 2005-08-02 | 2011-09-06 | 3M Innovative Properties Company | Apparatus and method for detecting an analyte |
WO2007016693A2 (en) * | 2005-08-02 | 2007-02-08 | 3M Innovative Properties Company | Flexible apparatus and method for detecting an analyte |
WO2007016693A3 (en) * | 2005-08-02 | 2007-05-31 | 3M Innovative Properties Co | Flexible apparatus and method for detecting an analyte |
US8480976B2 (en) | 2007-06-21 | 2013-07-09 | Gen-Probe Incorporated | Instruments and methods for mixing the contents of a detection chamber |
US8765367B2 (en) | 2007-06-21 | 2014-07-01 | Gen-Probe Incorporated | Methods and instruments for processing a sample in a multi-chambered receptacle |
US11235294B2 (en) | 2007-06-21 | 2022-02-01 | Gen-Probe Incorporated | System and method of using multi-chambered receptacles |
US7767447B2 (en) | 2007-06-21 | 2010-08-03 | Gen-Probe Incorporated | Instruments and methods for exposing a receptacle to multiple thermal zones |
US8048375B2 (en) | 2007-06-21 | 2011-11-01 | Gen-Probe Incorporated | Gravity-assisted mixing methods |
US8052929B2 (en) | 2007-06-21 | 2011-11-08 | Gen-Probe Incorporated | Gravity-assisted mixing methods |
US11235295B2 (en) | 2007-06-21 | 2022-02-01 | Gen-Probe Incorporated | System and method of using multi-chambered receptacles |
US8491178B2 (en) | 2007-06-21 | 2013-07-23 | Gen-Probe Incorporated | Instruments and methods for mixing the contents of a detection chamber |
US8735055B2 (en) | 2007-06-21 | 2014-05-27 | Gen-Probe Incorporated | Methods of concentrating an analyte |
US7780336B2 (en) | 2007-06-21 | 2010-08-24 | Gen-Probe Incorporated | Instruments and methods for mixing the contents of a detection chamber |
US10744469B2 (en) | 2007-06-21 | 2020-08-18 | Gen-Probe Incorporated | Multi-chambered receptacles |
US8784745B2 (en) | 2007-06-21 | 2014-07-22 | Gen-Probe Incorporated | Methods for manipulating liquid substances in multi-chambered receptacles |
US8828654B2 (en) | 2007-06-21 | 2014-09-09 | Gen-Probe Incorporated | Methods for manipulating liquid substances in multi-chambered receptacles |
US10688458B2 (en) | 2007-06-21 | 2020-06-23 | Gen-Probe Incorporated | System and method of using multi-chambered receptacles |
US9744506B2 (en) | 2007-06-21 | 2017-08-29 | Gen-Probe Incorporated | Instruments for mixing the contents of a detection chamber |
EP2138233A1 (en) * | 2008-06-02 | 2009-12-30 | Boehringer Ingelheim microParts GmbH | Microfluid film structure for metering liquids |
US9253777B2 (en) | 2009-04-27 | 2016-02-02 | Telefonaktiebolaget L M Ericsson (Publ) | Methods and apparatus in a wireless communication system |
US8780688B2 (en) | 2009-04-27 | 2014-07-15 | Telefonaktiebolaget Lm Ericsson (Publ) | Methods and apparatus in a wireless communication system |
WO2010126419A1 (en) * | 2009-04-27 | 2010-11-04 | Telefonaktiebolaget L M Ericsson (Publ) | Methods and arrangements in a wireless communication system |
Also Published As
Publication number | Publication date |
---|---|
DE69317502D1 (en) | 1998-04-23 |
TW313588B (en) | 1997-08-21 |
DK0594260T3 (en) | 1998-10-07 |
FI934669A (en) | 1994-04-24 |
EP0594260B1 (en) | 1998-03-18 |
JP3795540B2 (en) | 2006-07-12 |
JPH06197797A (en) | 1994-07-19 |
DE69317502T2 (en) | 1998-08-20 |
FI934669A0 (en) | 1993-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5422271A (en) | Nucleic acid material amplification and detection without washing | |
EP0594260B1 (en) | Nucleic acid material amplification and detection | |
EP0530357B1 (en) | Element and method for nucleic acid amplification and detection using adhered probes | |
Findlay et al. | Automated closed-vessel system for in vitro diagnostics based on polymerase chain reaction | |
US5380489A (en) | Element and method for nucleic acid amplification and detection using adhered probes | |
US7932093B2 (en) | One step oligochromatographic device and method of use | |
AU2010311138B2 (en) | Device and apparatus | |
US6251660B1 (en) | Devices and methods for detecting target molecules in biological samples | |
JP3034954B2 (en) | Reaction tubes and methods of use to minimize contamination | |
WO1991015768A1 (en) | Process and composition for performing dna assays | |
Verlander | Detection of horseradish peroxidase by colorimetry | |
EP0572057A1 (en) | PCR reagent composition, test kit and methods for amplification and detection with reduced nonspecific amplification of nucleic acids | |
EP0796917B1 (en) | Vehicle for delivery of particles to a sample | |
EP1045030A2 (en) | Amplification and detection of campylobacter jejuni and campylobacter coli | |
US6066455A (en) | Method of detecting nucleic acids | |
EP0768519B1 (en) | Container for staining of cells and tissues in combination with a roller and a support | |
US6485915B1 (en) | Analytical element for species-specific detection of nucleic acids | |
EP2660334B1 (en) | Positive control concept | |
US6197514B1 (en) | Amplification and detection of Yersinia enterocolitica | |
WO2004042084A1 (en) | Dry reagent strip and nucleic acid detection | |
Aubert et al. | Accelerated detection of DNA on membranes by automated enzyme-linked immunofiltration assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE DK FR GB IE IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19941006 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CLINICAL DIAGNOSTIC SYSTEMS, INC. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. |
|
17Q | First examination report despatched |
Effective date: 19960517 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE DK FR GB IE IT LI LU NL SE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
REF | Corresponds to: |
Ref document number: 69317502 Country of ref document: DE Date of ref document: 19980423 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: 79363 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. Free format text: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER NEW YORK 14650 (US) -TRANSFER TO- JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER NEW YORK 14650 (US) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20121031 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20121010 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20121018 Year of fee payment: 20 Ref country code: IE Payment date: 20121010 Year of fee payment: 20 Ref country code: CH Payment date: 20121012 Year of fee payment: 20 Ref country code: DE Payment date: 20121017 Year of fee payment: 20 Ref country code: BE Payment date: 20121018 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20121011 Year of fee payment: 20 Ref country code: IT Payment date: 20121013 Year of fee payment: 20 Ref country code: GB Payment date: 20121017 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20121010 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69317502 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Effective date: 20131021 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V4 Effective date: 20131021 |
|
BE20 | Be: patent expired |
Owner name: *JOHNSON & JOHNSON CLINICAL DIAGNOSTICS INC. Effective date: 20131021 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20131020 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20131022 Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20131021 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20131020 |